Gene	Rationale	Types_of_recurrent_alterations	Agents_TherapyABL1	"Translocations predict sensitivity to TKIs like imatinib, dasatinib, nilotinib.  Secondary mutations can cause resistance"	Rearrangement; Mutation	"Imatinib, Dasatinib, Nilotinib"AKT1	Mutations may predict sensitivity to AKT/MTOR inhibitors	Mutation	AKT/MTOR inhibitorsAKT2	Mutations may predict sensitivity to AKT/MTOR inhibitors	Mutation; Amplification	AKT/MTOR inhibitorsAKT3	Mutations may predict sensitivity to AKT/MTOR inhibitors	Rearrangement; Mutation	AKT/MTOR inhibitorsALK	Translocations predict sensitivity to crizotinib.  Secondary mutations can cause resistance.  Amplification and activating mutations may also be sensitive to crizotinib	Rearrangement; Mutation; Amplification	CrizotinibAPC	Biallelic inactivation may predict sensitivity to inhibitors of WNT signaling or anti-TRAIL antibodies. Also prognostic/diagnostic due to germline mutations	Biallelic Inactivation	WNT inhibitorsAR	Amplification may predict resistance to androgen deprivation in prostate cancer and may predict sensitivity to MDV3100	Amplification	"Andorgen DeprivationMDV3100"ARAF	Activating mutations may predict sensitivity to sorafenib	Mutation	SorafenibASXL1	Prognostic in MDS	Mutations	ATM	Biallelic inactivation predict sensitivity to PARP inhibitors	Biallelic Inactivation	PARP InhibitorATR	Biallelic inactivation predict sensitivity to PARP inhibitors	Biallelic Inactivation	PARP InhibitorAURKA	Amplifications are prognostic in colon cancer.  Also a target of Therapy	Amplification	AURKA InhibitorBAP1	Biallelic inactivation may predict sensitivity to HDAC inhibitors	Biallelic inactivation	HDAC InhibitorsBCL2	Translocation is prognostic/diagnostic in some hematologic cancers and activating alterations may be sensitive to BCL2 inhibitors	Rearrangement	? BCL2 inhibitorsBRAF	Mutations predict sensitivity to RAF inhibitors. Amplification may predict resistance to MEK inhibitors.	Mutation; Amplification; Rearrangement	"VemurafenibMEK inhibitors"BRCA1	Biallelic inactivation predict sensitivity to PARP inhibitors. Also prognostic/diagnostic due to germline mutations.	Biallelic Inactivation	PARP InhibitorBRCA2	Biallelic inactivation predict sensitivity to PARP inhibitors. Also prognostic/diagnostic due to germline mutations.	Biallelic Inactivation	PARP InhibitorBRD2	"Sensitivity to HDAC inhibitors, bromodomain inhibitors"	Rearrangement	"HDAC InhibitorsBromodomain inhibitors"BRD3	"Sensitivity to HDAC inhibitors, bromodomain inhibitors"	Rearrangement	"HDAC InhibitorsBromodomain inhibitors"BRD4	"Sensitivity to HDAC inhibitors, bromodomain inhibitors"	Rearrangement	"HDAC InhibitorsBromodomain inhibitors"CCND1	Amplification may predict resistance to hormone therapy in breast cancer. Amplification may be prognostic in breast cancer.  Amplification may predict sensitivity to CDK4/6 inhibitors. Translocations are diagnostic/prognostic in some hematologic cancers.	Amplification; Rearrangement	"Hormone therapyCDK 4/6 inhibitor"CCND2	Amplification may predict sensitivity to CDK4/6 inhibitors.	Rearrangement	? CDK inhibitorsCCND3	Amplification may predict sensitivity to CDK4/6 inhibitors.	Rearrangement	? CDK inhibitorsCCNE1	Amplification may predict sensitivity to CDK2 inhibitors.	Amplification	CKD 2 inhibitorCDH1	Prognostic / Diagnostic	Mutation	CDK4	Amplification may predict sensitivity to CDK4/6 inhibitors.	Amplification; Mutation	CDK 4/6 inhibitorCDK6	Amplification may predict sensitivity to CDK4/6 inhibitors.	Amplification; Rearrangement	CDK 4/6 inhibitorCDKN1A	Deletion may predict sensitivty to CDK inhibitors	Biallelic Inactivation	CDK 4/6 inhibitorCDKN1B	Deletion may predict sensitivty to CDK inhibitors	Biallelic Inactivation	CDK 4/6 inhibitorCDKN2A	Biallelic inactivation may predict sensitivity to CDK4/6 inhibitors.	Biallelic Inactivation	CDK 4/6 inhibitorCDKN2B	Biallelic inactivation may predict sensitivity to CDK4/6 inhibitors.	Biallelic Inactivation	CDK 4/6 inhibitorCEBPA	Biallelic inactiavtion is an indication for transplant in AML. Sensitivity to CDK inhibitors	Biallelic Inactivation	TransplantCREBBP	Biallelic inactivation is Prognostic / Diagnostic in leukemia	Biallelic Inactivation	CDK 4/6 inhibitorCRKL	Amplification may result in resistance to EGFR inhibition and RAF inhibition. Amplification may predict sensitivity to SRC inhibitors.	Amplification	Vemurafenib; SRC inhibitorsCTNNB1	Possibly prognostic in colon cancer; maybe some resistance stuff in lung cancer and melanoma; possibly targetable with WNT inhibitors (see APC above) <NEED TO FILL IN>	Mutations	? WNT inhibitorsDDR2	Mutations may predict sensitivity to dasatinib (see Hammerman Cancer Discovery paper)	Mutations	DasatinibDNMT3A	Some mutations may be sensitive to DNA methylransferace inhibitors.  Some may be prognostic in leukemia	Mutations	DNAMT inhibitorsEGFR	"Mutations targetable with TKIs (both FDA approved and novel). Other mutations predict resistance to TKIs.  Amplification associated with response to anti-EGFR Abs in colon cancer. Amplification also associated with resistance to TKIs in some cancers.  Rearangement is prognostic in GBM, HNSCC"	Mutation; Amplification; Rearrangement	"Erlotinib, GefitinibNovel EGFR Inhibitors"EPHA3	Alterations may predict sensitivity to dasatinib	Mutation; Amplification	DasatinibEPHA5	Alterations may predict sensitivity to dasatinib	Mutation	DasatinibERBB2	Amplifications predict sensitivity to anti-Her2 therapy. <what about mutations?>	Amplification; Mutations	"Trastuzumab, Lapatinib"ERBB3	Alterations may be sensitive to pertuzumab or novel HER3 inhibitors	Mutations	PertuzumabERBB4	Mutations may predict sensitivity to Lapatinib and other anti-EGF family inhibitors	Mutation	LapatinibERG	"Fusion with TMPRSS2 shown to potentiate sensitivity to PARP inhibitors in vitro (Brenner JC, Cancer Cell, 2011)"	Rearrangement	PARP InhibitorESR1	Amplification may predict ER positivity in breast cancer	Amplification	Hormonal therapyETV1	Diagnostic	Rearrangement	ETV4	Diagnostic	Rearrangement	ETV5	Diagnostic	Rearrangement	ETV6	Diagnostic	Rearrangement	EWSR1	Diagnostic	Rearrangement	EZH2	"Negative prognostic factor in MDS.  Targetable with EZH2 inhibitors, in development."	Mutations	? HDAC inhibitor?FBXW7	Mutation or loss may predict sensitivity to MTOR inhibitors.  Mutations or loss may predict resistance to anti-tubulin chemotherapy	Biallelic Inactivation	"MTOR inhibitorsTubulins"FGFR1	Amplification predicts resistance to hormonal therapy in breast cancer.  Amplification predicts sensitivity to FGFR inhibitors	Amplification	FGFR InhibitorsFGFR2	Alterations may predict sensitivity to FGFR inhibitors	Mutations	FGFR InhibitorsFGFR3	Alterations may predict sensitivity to FGFR inhibitors	Mutations	FGFR InhibitorsFLT3	"Mutations predict sensitivity to FLT3 inhibitors, sunitinib.  Secondary mutations predict resistance."	Mutation	"Sunitinib, FLT3 inhibitors"GNA11	Mutations may predict sensitivity to MAPK pathway inhibitors	Mutation	MAPK pathway inhibitorsGNAQ	Mutations may predict sensitivity to MAPK pathway inhibitors	Mutation	MAPK pathway inhibitorsGNAS	"Mutations may be diagnostic of tumors arising in McCune-Albright syndrome, and may be targetable with JAK inhibitors"	Mutation	JAK inhibitorsHRAS	Mutations may predict sensitivity to MAPK pathway inhibitors.  Mutations may predict resistance to TKIs.	Mutation	MAPK pathway inhibitorsIDH1	Prognostic / Diagnostic	Mutation	<in development>IDH2	Prognostic / Diagnostic	Mutation	<in development>IGF1R	Amplification may predict senitivity to IGFR1-R inhibitors	Amplification	IFG1-R InhibitorJAK2	Mutations may predict sensitivity to JAK2 inhibitors	Mutation	JAK inhibitorsJAK3	Mutations may predict sensitivity to JAK3 inhibitors	Mutation	JAK inhibitorsKDR	Activating mutations may predict sensitivity to specific inhibitors	Mutations	KDR inhibitorsKIT	Mutations targetable with TKIs (both FDA approved and novel). Secondary mutations predict resistance to TKIs.  Amplification also associated with resistance to TKIs.	Mutation; Amplification	"Imatinib, SunitinibNovel KIT Inhibitors"KRAS	"Mutations may predict resistance to anti-EGFR therapies (cetuximab, ant-EGFR TKIs).  Mutations may predict sensitivity to MEK inhibitors.  Mutations may be directly targetable by some therapies (immunotherapies, viruses).  Prognostic in some cancer types."	Mutation	"CetuximabMEK inhibitors"MAP2K1	Mutations predict resistance to RAF- and MEK- inhibitor	Mutation	"Vemurafenib, MEK inhibitors"MAP2K2	Activating mutations may predict sensitivty to MEK2 inhibitors	Mutations	MEK2 inhibirosMAP2K4	"Orthologue of Targetable, CGC"	Mutations	MAP2K4 inhibitorsMCL1	Amplification may predict resistance to anti-tubulin chemotherapy	Amplification	TubulinsMDM2	Amplification may predict sensitivity to Nutlins and MDM2 inhibitors	Amplification	NutlinMDM4	Amplification may predict sensitivity to Nutlins and MDM4 inhibitors	Amplification	? NutlinMEN1	Prognostic / Diagnostic (also germline)	Biallelic Inactivation	MET	Amplification may cause resistance to anti-EGFR TKIs.  Amplification may predict sensitivity to MET-inhibitors	Amplification	"Gefitinib, ErlotinibMET inhibitors"MITF	Prognostic / Diagnostic (also germline)	Mutation	MLH1	Prognostic / Diagnostic in colon cancer	Biallelic Inactivation	MLL	Translocations are prognostic / diagnostic. Alterations may be sensitive to HDAC inhibitors or novel inhibitors in development	Rearrangement	HDAC InhibitorsMPL	Mutation may predict sensitivity to JAK2 inhibitor	Mutation	JAK2 inhibitorsMSH2	Prognostic / Diagnostic in colon cancer	Biallelic Inactivation	MSH6	Prognostic / Diagnostic in colon cancer	Biallelic Inactivation	MTOR	Activating mutations may predict sensitivity to MTOR inhibitors	Mutation	MTOR inhibitorsMYC	Prognostic / Diagnostic 	Amplification	NF1	Biallelic inactivation may predict sensitivity to PI3K pathway inhibitors (PI3K/AKT/MTOR) and/or MAPK pathway inhibitors (RAF/MEK/ERK).	Biallelic Inactivation	"PI3K/AKT/MTOR inhibitorsRAF/MEK/ERK inhibitors"NF2	? Biallelic inactivation may predict sensitivity to PI3K pathway inhibitors (PI3K/AKT/MTOR) and/or MAPK pathway inhibitors (RAF/MEK/ERK).	Biallelic Inactivation	"PI3K/AKT/MTOR inhibitorsRAF/MEK/ERK inhibitors"NFKBIA	Deletion is prognostic in GBM	Deletions	NKX2-1	Diagnostic	Amplification	NOTCH1	Activating mutations and rearrangements may predict sensitivity to Notch inhibitors	Mutation; Rearrangement	Notch InhibitorsNOTCH2	Activating mutations may predict sensitivity to Notch inhibitors	Mutation	Notch InhibitorsNPM1	Mutations are an indication for transplant in AML	Mutations; Rearrangement	TransplantNRAS	Mutations predict resistance to RAF- inhibitors	Mutation	"?Vemurafenib"NTRK3	"Fusion with ETS factors (in secretory breast cancer, for example) may predict sensitivity to PI3K pathway inhibitors, SRC inhibitors, and/or IGF1-R inhibitors"	Rearrangement	"PI3K/AKT/MTOR inhibitorsDasatinib or other src inhibitorsIGF1-R inhibitors"NUT	"Sensitivity to HDAC inhibitors, bromodomain inhibitors"	Rearrangement	"HDAC InhibitorsBromodomain inhibitors"PDGFRA	Mutations predict sensitivity to imatinib	Mutation; Rearrangement	ImatininbPDGFRB	Alterations predict sensitivity to imatinib	Rearrangement	ImatininbPIK3CA	"Mutations may predict sensitivity to PI3K pathway inhibitors -- PI3K inhibitors, AKT inhibitors, and MTOR inhibitors.  Mutations may predict resistance to anti-RTK therapy, including cetuximab, anti-EGFR TKIs, and trastuzumab and lapatinib"	Mutations	PI3K/AKT/MTOR inhibitorsPIK3R1	"Mutations may predict sensitivity to PI3K pathway inhibitors -- PI3K inhibitors, AKT inhibitors, and MTOR inhibitors."	Mutations	PI3K/AKT/MTOR inhibitorsPTCH1	Mutations may predict sensitivity to hedgehog inhibitors	? Lookup	VismodegibPTEN	"Biallelic inactivation may predict sensitivity to PI3K pathway inhibitors -- PI3K inhibitors, AKT inhibitors, and MTOR inhibitors.  Biallelic inactivation may predict resistance to anti-RTK therapy, including cetuximab, anti-EGFR TKIs, and trastuzumab and lapatinib.  Biallelic inactivation may predict sensitivity to PARP inhibitors"	Biallelic Inactivation	PI3K/AKT/MTOR inhibitorsRAF1	Alterations may predict sensitivity to RAF inhibitors.  Amplification may predict resistance to specific RAF inhibitors (like vemurafenib). 	Mutation; Amplification; Rearrangement	"SorafenibRAF inhibitors"RARA	Transloactions predict sensitivity to ATRA and arsenic	Rearrangement	"ATRA, Arsenic"RB1	Prognostic / Diagnostic (germline)	Biallelic Inactivation	RET	Mutations and fusion may predict sensitivity to RET inhibitors	Mutation; Rearrangement	"Sorafenib, vandetinibOther RET Inhibitors"ROS1	Fusions Sensitive to Crizotinib	Rearrangement	CrizotinibRUNX1	Prognostic / Diagnostic	Rearrangement	SMAD2	Prognostic / Diagnostic in colon cancer	Biallelic Inactivation	SMAD4	Prognostic / Diagnostic in colon cancer	Biallelic Inactivation	SMARCA4	Inactivation may predict sensitivity to HDAC inhibitors	Biallelic Inactivation	HDACSMARCB1	"Inactivation may predict sensitivity to CDK Inhibitors, Hedgehog Inhibitors, and/or HDAC Inhibitors"	Biallelic Inactivation	"CDK inhibitorsVismodegibHedgehog inhibitorsHDAC inhibitors"SMO	Mutations may predict sensitivity to hedgehog inhibitors	Mutations	VismodegibSTK11	Biallelic inactivation may predict sensitivity to MTOR inhibitors.  Biallelic inactiavtion may predict sensitivity to SRC or FAK inhibitors (Cancer Cell 2010)	Biallelic Inactivation	"MTOR inhibitorsDasatinibFAK inhibitors"SYK	Activating mutations may predict sensitivity to Syk inhibitors	Mutation	SYK inhibitorsTET2	Prognostic / Diagnostic in MDS 	Mutations	TMPRSS2	Prognostic / Diagnostic	Rearrangement	TP53	Biallelic inactivation or mutation may be prognostic in some tumor types.  They may also predict sensitivity to some p53 specific gene therapies or immunotherapies 	Biallelic Inactivation	Anti-p53 therapiesTSC1	Biallelic inactivation may predict sensitivity to MTOR inhibitors	Biallelic Inactivation	MTOR inhibitorsTSC2	Biallelic inactivation may predict sensitivity to MTOR inhibitors	Biallelic Inactivation	MTOR inhibitorsVHL	Prognostic / Diagnostic (germline)	Biallelic Inactivation	WT1	Prognostic / Diagnostic (germline)	Biallelic Inactivation	XPO1	Mutations may predict sensitivity to small molecule selective inhibitors of nuclear export (SINE) 	Mutation	SINE agentsc15orf55	"Sensitivity to HDAC inhibitors, bromodomain inhibitors"	Rearrangement	HDAC inhibitors